TetraGenetics, an AbCellera company, empowers antibody discovery against difficult-to-drug targets by providing high quality recombinant transmembrane proteins, including human ion channels, G protein-coupled receptors and other transmembrane proteins.
Transmembrane proteins, which are implicated in many human diseases, are both difficult to produce and difficult to drug. TetraGenetics’ protein production platform, TetraExpress™, uses the protist Tetrahymena thermophila to quickly produce large quantities of properly folded, functional transmembrane proteins. This solves the protein production challenge, providing the critical reagents needed throughout the antibody discovery process, from immunization and screening to characterization and protein engineering.
Transmembrane proteins, which are implicated in many human diseases, are both difficult to produce and difficult to drug. TetraGenetics’ protein production platform, TetraExpress™, uses the protist Tetrahymena thermophila to quickly produce large quantities of properly folded, functional transmembrane proteins. This solves the protein production challenge, providing the critical reagents needed throughout the antibody discovery process, from immunization and screening to characterization and protein engineering.
Location: United States, Massachusetts, Arlington
Employees: 11-50
Total raised: $1.54M
Founded date: 2004
Investors 4
| Date | Name | Website |
| - | Bantam Gro... | bantamgrou... |
| - | Excell Par... | excellny.c... |
| - | T1D Fund | t1dfund.or... |
| - | Launchpad ... | launchpadv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.01.2016 | Grant | $1.54M | - |
Mentions in press and media 3
| Date | Title | Description |
| 02.05.2017 | Term Sheet — Tuesday, May 2 | PUTTING THE SILICON IN SILICON VALLEY Today we have another installment in Term Sheet’s series of interviews with dealmakers at the tech industry’s most active acquirers. Cisco is an acquisition machine, having done nearly 200 deals in its ... |
| 02.05.2017 | TetraGenetics Raises Funding from JDRF T1D Fund | TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced it has received an investment in the company’s type 1 diabetes (T1D) program from the JDRF T1D Fund, a venture philanthropy fu... |
| 14.01.2016 | Tetragenetics Receives $1.54m Grant from NIGMS | Tetragenetics Inc., an Arlington, MA-based biotechnology company engaged in the expression of ion channel drug targets, received an approx. $1.54m grant from the National Institute of General Medical Sciences (NIGMS) of the National Institu... |